Stock comparison
Genmab A/S
Regeneron Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
REGN
Regeneron Pharmaceuticals
Market cap
$65.82B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | REGN | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 64C | GMAB |
| Benjamin Graham | 64C | 68B | REGN |
| Philip Fisher | 48D | 48D | Tie |
| Peter Lynch | 25F | 26F | REGN |
| Joel Greenblatt | 76B | 45D | GMAB |
| Charlie Munger | 68C | 59C | GMAB |
| Terry Smith | 71C | 57C | GMAB |
Side-by-side metrics
| Metric | GMAB | REGN |
|---|---|---|
| Market cap | $16.5B | $65.82B |
| P/E (TTM) | 6.2x | 16.4x |
| EV/EBIT | 12.0x | 20.0x |
| ROIC (TTM) | 43.78% | 8.53% |
| Gross margin | 93.88% | 84.55% |
| Net margin | 18.23% | 29.65% |
| Revenue CAGR 5y | -18.45% | -2.81% |
| EPS CAGR 5y | -23.48% | -13.35% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.51% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 8.53%+81%
- P/E (TTM)6.2xvs 16.4x+63%
- EV/EBIT12.0xvs 20.0x+40%
- Debt / Equity0.1xvs 0.1x+15%
REGN leads on
- Dividend yield0.51%vs 0.0%+100%
- Revenue CAGR 5y-2.81%vs -18.45%+85%
- Market cap$65.82Bvs $16.5B+75%
- EPS CAGR 5y-13.35%vs -23.48%+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.